Show simple item record

dc.contributor.authorStratton, M
dc.date.accessioned2018-06-08T15:04:27Z
dc.date.issued2010-11
dc.identifier11
dc.identifier.citationGENES CHROMOSOMES & CANCER, 2010, 49 pp. 1062 - 1069
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1777
dc.description.abstractDetection of recurrent somatic rearrangements routinely allows monitoring of residual disease burden in leukemias, but is not used for most solid tumors. However, next-generation sequencing now allows rapid identification of patient-specific rearrangements in solid tumors. We mapped genomic rearrangements in three cancers and showed that PCR assays for rearrangements could detect a single copy of the tumor genome in plasma without false positives. Disease status, drug responsiveness, and incipient relapse could be serially assessed. In future, this strategy could be readily established in diagnostic laboratories, with major impact on monitoring of disease status and personalizing treatment of solid tumors. (C) 2010 Wiley-Liss, Inc.
dc.format.extent1062 - 1069
dc.languageeng
dc.language.isoeng
dc.publisherWILEY-LISS
dc.titleUse of Cancer-Specific Genomic Rearrangements to Quantify Disease Burden in Plasma from Patients with Solid Tumors
dc.typeJournal Article
rioxxterms.licenseref.startdate2010-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfGENES CHROMOSOMES & CANCER
pubs.noteskeywords: CELL LUNG-CANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; PROSTATE-CANCER; RT-PCR; MUTATIONS; DNA; GENE; IDENTIFICATION; FUSION
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Genetic Susceptibility
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Genetic Susceptibility
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Genetic Susceptibility
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Genetic Susceptibility
pubs.volume49
pubs.embargo.termsNot known
pubs.oa-locationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145117/
icr.researchteamGenetic Susceptibilityen_US
dc.contributor.icrauthorStratton, Michaelen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record